和邦生物
(603077)
| 流通市值：181.92亿 | | | 总市值：181.92亿 |
| 流通股本：88.31亿 | | | 总股本：88.31亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,813,692,192.92 | 4,848,440,513.18 | 1,999,261,196.4 | 8,824,107,811.82 |
| 营业收入 | 6,813,692,192.92 | 4,848,440,513.18 | 1,999,261,196.4 | 8,824,107,811.82 |
| 二、营业总成本 | 6,550,036,297.8 | 4,604,210,077.7 | 1,944,326,999.84 | 7,325,629,073.21 |
| 营业成本 | 6,084,665,992.82 | 4,306,910,058.74 | 1,797,137,427.2 | 6,771,569,678.96 |
| 税金及附加 | 51,870,369.73 | 38,620,430.69 | 11,658,160 | 66,250,890.75 |
| 销售费用 | 54,203,613.62 | 33,218,491.64 | 16,371,720.91 | 59,562,386.76 |
| 管理费用 | 304,668,291.44 | 195,640,133.26 | 106,560,740.12 | 413,402,434.68 |
| 研发费用 | 22,518,887.99 | 14,793,583.58 | 8,346,347.48 | 47,346,892.37 |
| 财务费用 | 32,109,142.2 | 15,027,379.79 | 4,252,604.13 | -32,503,210.31 |
| 其中:利息费用 | 60,444,305.77 | 37,103,561.37 | 16,275,155.93 | 24,372,822.46 |
| 其中:利息收入 | 30,231,339.88 | 17,996,096.84 | 9,143,232.91 | 60,351,444.11 |
| 加:投资收益 | -1,258,619.26 | -300,197.85 | -735,649.12 | 75,219,142.94 |
| 资产处置收益 | -23,698.1 | -36,244.07 | -46,772.1 | 808,182.23 |
| 资产减值损失(新) | -6,531,466.9 | -3,927,034.19 | - | -36,752,062.95 |
| 信用减值损失(新) | -9,321,151.14 | -5,920,773.67 | -14,527,656.52 | -13,456,089.38 |
| 其他收益 | 13,778,779.35 | 11,721,112.7 | 3,988,080.03 | 17,494,204.69 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 260,299,739.07 | 245,767,298.4 | 43,612,198.85 | 1,541,792,116.14 |
| 加:营业外收入 | 27,901.58 | 17.36 | 4.63 | 3,215,517.64 |
| 减:营业外支出 | 826,181.95 | 446,438.64 | 3,601.46 | 9,042,112.79 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 259,501,458.7 | 245,320,877.12 | 43,608,602.02 | 1,535,965,520.99 |
| 减:所得税费用 | 63,964,479.66 | 57,272,517.57 | 16,465,391.27 | 257,266,260.36 |
| 六、净利润 | 195,536,979.04 | 188,048,359.55 | 27,143,210.75 | 1,278,699,260.63 |
| 持续经营净利润 | 195,536,979.04 | 188,048,359.55 | 27,143,210.75 | 1,278,699,260.63 |
| 归属于母公司股东的净利润 | 221,318,621.02 | 192,269,822.59 | 29,792,564.09 | 1,283,243,893.34 |
| 少数股东损益 | -25,781,641.98 | -4,221,463.04 | -2,649,353.34 | -4,544,632.71 |
| (一)基本每股收益 | 0.03 | 0.02 | 0 | 0.15 |
| (二)稀释每股收益 | 0.03 | 0.02 | 0 | 0.15 |
| 八、其他综合收益 | -33,076,482.29 | -16,366,171 | 1,488,590.74 | 31,687,239.44 |
| 归属于母公司股东的其他综合收益 | -31,653,244.96 | -16,529,622.57 | 1,311,974.79 | 28,964,431.54 |
| 九、综合收益总额 | 162,460,496.75 | 171,682,188.55 | 28,631,801.49 | 1,310,386,500.07 |
| 归属于母公司股东的综合收益总额 | 189,665,376.06 | 175,740,200.02 | 31,104,538.88 | 1,312,208,324.88 |
| 归属于少数股东的综合收益总额 | -27,204,879.31 | -4,058,011.47 | -2,472,737.39 | -1,821,824.81 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |